ResultsIQ › Latest results › Borosil Scientific Limited
Borosil Scientific Limited Q2 FY27 results deck summary
NSE: BOROSCI · BSE: 544184
Results deck of 31 Oct 2026, summarised by AI from the filing.
Borosil Scientific's Q2 FY27 consolidated PAT rose 86.3% to ₹5.3 cr on net sales of ₹115.0 cr, with glassware capacity set to expand by March 2027.
Key takeaways
- Consolidated PAT Consolidated PAT was ₹5.3 cr in Q2 FY27 (Q2 FY26: ₹2.9 cr, +86.3%), on net sales of ₹115.0 cr (+7.5%).
- Medium-term goals Management targets revenue CAGR of 12-14% and EBITDA margin improvement over the medium term.
- Segment reporting Primary Pharma Packaging and Consumer Glassware are now reported as separate segments, with prior periods restated.
- Capacity expansion Glassware capacity is to rise from ~15 to ~108 lakh units p.a. by March 2027 at ₹60 cr capex.
- Input costs Higher input costs from Middle East geopolitical tensions hit standalone profitability in Q2 FY27 and H1 FY27.
Borosil Scientific Limited Q2 FY27 results
As filed: Revenue ₹115 cr (+7% year on year), EBITDA ₹10.7 cr (+34% year on year), PAT ₹5.3 cr (+77% year on year), EBITDA margin 9.3% (+183 bps).
The Q2 FY27 score, against the company's own trend, is for premium members.
Earlier results and the share price after them
- Q1 FY27: Revenue ₹107 cr (+11% year on year), EBITDA ₹8.5 cr (+69% year on year), PAT ₹4.4 cr, EBITDA margin 7.9% (+271 bps). Score 53 of 100, In line with trend. Revenue and EBITDA growth were above the company's own trend. EBITDA margin rose 271 bps year on year. Other income 45% of PBT. Revenue fell 25% from last quarter. Share price after the results: −14.4% in 30 days (Nifty 500: −2.4%).
- Q4 FY26: Revenue ₹143 cr (+11% year on year), EBITDA ₹32.1 cr (+101% year on year), PAT ₹27.3 cr (+203% year on year), EBITDA margin 22.4% (+1,000 bps). Score 79 of 100, Above trend. EBITDA margin rose 1000 bps year on year. Tax rate 7%. Not enough history for a trend yet: scored on growth alone. Share price after the results: +29.6% in 30 days (Nifty 500: +2.8%).
- Q3 FY26: Revenue ₹121 cr (+20% year on year), EBITDA ₹17.2 cr (+72% year on year), PAT ₹8.7 cr (+108% year on year), EBITDA margin 14.2% (+428 bps). Score 89 of 100, Above trend. EBITDA margin rose 428 bps year on year. Not enough history for a trend yet: scored on growth alone. Share price after the results: −1.2% in 30 days (Nifty 500: −10.1%).
- Q2 FY26: Revenue ₹107 cr (+4% year on year), EBITDA ₹8.0 cr (−47% year on year), PAT ₹3.0 cr (−67% year on year), EBITDA margin 7.5% (−709 bps). Score 0 of 100, Below trend. EBITDA margin fell 709 bps year on year. Other income 40% of PBT. Tax rate 40%. Consolidated profit -67% but standalone +0%. Not enough history for a trend yet: scored on growth alone. Share price after the results: −7.8% in 29 days (Nifty 500: +1.4%).
- Q1 FY26: Revenue ₹96.0 cr (−8% year on year), EBITDA ₹5.0 cr (−50% year on year), PAT −₹4.0 cr (−57% year on year), EBITDA margin 5.2% (−441 bps). Score 6 of 100, Below trend. EBITDA margin fell 441 bps year on year. Not enough history for a trend yet: scored on growth alone. Revenue fell 26% from last quarter. Share price after the results: −7.5% in 30 days (Nifty 500: +2.8%).
- Q4 FY25: Revenue ₹118 cr, EBITDA ₹21.0 cr, PAT ₹14.0 cr, EBITDA margin 17.8%. Not scored. No result for the same quarter last year. Share price after the results: −4.5% in 30 days (Nifty 500: +1.4%).
- Q3 FY25: Revenue ₹94.0 cr, EBITDA ₹11.0 cr, PAT ₹7.0 cr, EBITDA margin 11.7%. Not scored. No result for the same quarter last year.
Past price moves after results do not indicate future moves. Not a recommendation.
Borosil Scientific Limited earnings call, investor presentation and press release summaries
- Q2 FY27: Results deck (31 Oct 2026)
- Q1 FY27: Results deck (5 Aug 2026)
- Q4 FY26: Results deck (27 May 2026)
- Q3 FY26: Results deck (13 Feb 2026)
- Q2 FY26: Results deck (12 Nov 2025)
- Q1 FY26: Results deck (12 Aug 2025)
- Q4 FY25: Results deck (22 May 2025)
Figures from the company's filings with NSE and BSE. Not investment advice.